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The Chemical Prospectors
With little new ground gained in the war 
against cancer, no cure in sight for AIDS, and the 
looming threat of resistance to current antibiot­
ics, modern researchers have become as in­
trigued by new natural pharmaceuticals as 15th- 
century explorers were by spices. Collectors 
search for specimens around the world, in re­
mote jungles, coral reefs, marshes, and the depths 
of the ocean. And although it costs twice as much 
to get a specimen from the sea as it does to 
collect a terrestrial 
item, the effort is prov­
ing worthwhile. Today 
most natural com­
pounds that show 
promise as anti-can­
cer drugs come from 
the sea. These include 
six compounds that 
have reached clinical 
or late-preclinical tri­
als in the United States 
and Canada.
Marine chem­
ists say they have only 
just begun to tap the 
chemical diversity of 
the sea. “Man has 
been interacting with 
plants on land for 
some 3000 years,” says chemist William Fenical 
of the Scripps Institution of Oceanography. “In 
the ocean there are an incredible number of 
organisms - and we don’t know their potential."
And it is not just the U.S. researchers who 
are looking to the oceans. The Japanese gov­
ernment is starting to emphasize marine natural 
products, and Japan has become the world leader 
in the use of submersibles for collecting deep­
water organisms. So far, Japanese researchers 
haven’t found anything that has reached the 
clinical trial stage. Also, they don’t have a 
massive screening effort like the US National 
Cancer Institute (NCI). But Japanese scientists 
have isolated a number of potential anti-cancer 
and antibiotic compounds especially from deep-
sea bacteria, and used crystallography or other 
techniques to determine their chemical struc­
tures which are often strange and unique.
Toxic defense
One reason sea creatures are particularly 
promising sources of anti-cancer compounds, 
speculates NCI chemist David Newman, is that 
natural selection has forced them to develop 
elaborate chemical arsenals. The sea is full of 
sitting targets: soft- 
bodied, stationary, 
brightly colored crea­
tures that seem to say 
“eat me”, he says. To 
avoid that fate, those 
creatures rely on pow­
erful toxins. And toxic­
ity is the reason cancer 
drugs work - the goal is 
to poison tumor cells 
more than healthy cells.
Collectors look 
for soft bodies and other 
signs of helplessness. 
Most of the samples 
come from the warm 
tropics, and although it’s 
likely that those regions 
hold more biodiversity, 
a simpler explanation is that divers like the trop­
ics, as Newman says. “I’ve gone diving off Eng­
land. And it’s bloody cold...”
Research has been given a boost by the 
development of screening techniques based on 
the tools of molecular biology. These screens 
generally look for a compound’s effects on a 
specific chemical “target” -- usually an enzyme 
responsible for the growth of cancer cells. The 
speed of the molecular screens has revolution­
ized the search for drugs from natural products, 
says Crews. “You can screen thousands of things 
each day now.”
Using this new technology, Crews, in col­
laboration with researchers from Syntex in Cali­
fornia, has identified two possible cancer-fighting
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compounds from sponges. One is a class of 
compounds called bastadins that interfere with 
the growth of leukemic cells and ovarian tumors; 
the other is a compound called jasplakinolide, 
which disrupts cell division in cultured renal and 
prostate cancer cells. Jasplakinolide has a seri­
ous drawback as a potential therapeutic agent. It 
is so toxic that it killed all the lab animals exposed 
to it. The hope, however, is that chemists will be 
able to alter the compound’s structure to produce 
a milder derivative that retains enough toxicity to 
deal with tumor cells.
Researchers at Smith Kline Beecham are 
also using fast assays to plow through thousands 
of organisms they pluck from coral reefs, estuar­
ies, marine lakes, and even wrecked ships, says 
Brad Carte, a marine products chemist. “We look 
for anti-cancer drugs, anti-inflammatory, anti­
virals, anything you can think of.” They test 
extracts to see if they inhibit a target enzyme 
called a topoisomerase, enzymes that, by 
changing the topology of DNA, are important in 
the proliferation of cancer cells. They’ve used 
this to identify promising small molecules from 
several sponges from the Philippines and Japan, 
one of which has shrunk tumors in mice.
The company has also screened for 
chemicals that bind to an enzyme called protein 
kinase, which is essential for cell division and 
signal transduction -  the transfer of information 
from outside chemicals, such as growth factors 
and hormones, into cells. A drug acting against 
protein kinase might inhibit cancer growth or 
inflammation. Paul Scheuer of the University of 
Hawaii and his colleagues have identified protein 
kinase inhibitors from a sponge and a tunicate. 
And while NCI has found just one compound that 
has any effect on HIV, University of Chicago 
researchers have seen sponge extracts that in­
hibit HIV protease, an enzyme necessary for viral 
replication.
Microbial prospecting
While most researchers have been testing 
extracts from large organisms, others, including 
microbiologist Deborah Steinberg of American
Cyanamid, have been thinking small. They are 
scouring the seas for microorganisms with po­
tentially useful properties. She and her colleagues 
collect microbes from around the world and use 
a variety of molecular screens and tested them 
for signs of antibiotic, anti-cancer, or anti-viral 
properties, as well as potential for cardiovascular 
and central nervous system drugs. They test 
thousands per day right on the collection ship 
and have already found a number of leads. One 
is bioxalomycin -- a compound isolated from 
shoreline bacteria that shows antibacterial prop­
erties.
Scripps’s Fenical is now working with Bris­
tol-Myers Squibb to screen marine microbes for 
both anti-cancer and anti-inflammatory agents. 
Though his team searches water and sand, he’s 
actually found the most interesting samples on 
the bodies of other organisms. “We look on the 
surfaces of plants and animals,” he says, “in the 
tissues of fish and the digestive tracts of shrimp.”
Indeed, some of the toxins associated with 
macroscopic animals come from microbes that 
live in or on their bodies. Take tetrodotoxin, a 
deadly substance that concentrates in the puffer 
fish -  and occasionally kills daredevil gourmets 
who indulge in this high-risk delicacy. Japanese 
biochemists Takeshi Yasumoto of Tohoko Uni-
" I f a useful drug turns up, 
researchers could 
quickly face a problem: 
demand may 
outstrip supply. 
Researchers try to 
prevent that by 
developing techniques 
for farming marine 
organisms. "
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versity and Michlo Murata of the University of 
Tokyo recently discovered that tetrodotoxin 
comes from a type of unicellular marine bacteria 
living in the fish's internal organs.
Fenical has found that many marine crea­
tures and their eggs are covered with bacteria 
that protect their hosts from disease: “If you put 
organisms in polluted seawater and destroy the 
surface bacteria, the animals die because they 
get infected with pathogens.” That finding, he 
says, argues for seeking new antibiotics in such 
protective microbes. Already, he has interesting 
leads, including a powerful anti-fungal compound, 
called istatin, isolated from bacteria that protect 
shrimp eggs, and two possible antibiotics, 
salinamide A and B, in bacteria living on the 
body of a jellyfish found in Florida.
Supply and demand
If a useful drug does turn up, researchers 
could quickly face a problem: demand may out­
strip supply. Crews and other researchers are 
trying to prevent that by developing techniques 
for farming marine organisms. It can be a chal­
lenging task, however, for some creatures -  
sponges, for example -  are notoriously difficult to 
cultivate, says Crews. One group, headed by 
marine chemists Murray Munroe and John Blunt
at the University of Canterbury in New Zealand, 
has managed to start the first sponge farm, 
growing the sponge that produces halochondrin 
-- one of the six marine-based compounds that 
are moving toward clinical trials.
Microbes should be easier to grow, but 
even here, the strangeness of the marine world 
presents a challenge. “You have to reinvent 
microbiology,” says Fenical. Terrestrial bacteria 
are often grown in protein compounds or glu­
cose. But There’s no glucose in the sea.” So to 
grow marine microbes, he says, “we’ve devel­
oped about 25 media based on all kinds of 
concoctions - fish meals and powders, special 
oils, and crab shells. ... You have to think about 
what’s out there.”
Chemical prospecting among marine or­
ganisms is still in its early stages. But with several 
compounds showing promise in the lab and a 
handful moving toward clinical trials, researchers 
like Fenical are confident that it is just a matter of 
time before they hit pay dirt. And, when that 
happens, the big drug companies will follow. 
“Within the next 5 years companies will look into 
the ocean as they’ve never done before,” he 
says.
Excerpted from Science Vol. 266. November 25, 1994.
Ouch! That hurts!
Quite a long time ago, surgeons remove a 
section of bone from the skull to relieve pressure 
on the brain. First, the patient's head was shaved 
and the skin slit and drawn back, exposing the 
bone. Then a small surgical saw was used to 
remove the section, which was replaced when 
the drainage was completed. The hole remaining 
in the skull indicates that the patient died.
Surgeries in the 21st century are much less 
painful with the discovery of anaesthesia. 
Preventive drugs have also been discovered 
from both land-based and aquatic organisms. 
More bioactive compounds especially from 
aquatic organisms are being studied by 
scientists.
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